MAP2K7 and melanoma: In addition, in the randomized, phase III Combi-AD trial, evaluating the association of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib versus placebo in patients with BRAFV600 mutant melanoma, the results showed a significant improvement in RFS at 5 years, with 52% RFS in the dabrafenib plus trametinib arm versus 36% in the control group (HR, 0.51; 95% CI, 0.42 to 0.61) [6].